Picamilon: pharmaceutical composition — RU2149001C1
И.И. Тюляев, В.А. Быков, Б.И. Демченко, А.П. Зуев, Н.И. Юрченко · 2000 · RU2149001C1 · patent family 20224731
Published 2000-05-20.
Reported patent results
Narrative findings; numerical extraction incomplete
The final example reports successful tableting and compliance with pharmaceutical requirements.
Picamilon tablet-production examples comparing process moisture and tabletability; no patient efficacy experiment.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Process example outcome | At stated residual moisture of 3.9%, the material was described as tableting well and the resulting tablets as meeting requirements | Manufacturing observation, not absorption or clinical benefit |
| Clinical outcomes | No controlled cognition, anxiety or neurological-treatment result supplied by these formulation examples | Absence of clinical results is explicit |
A successful preparation example does not establish clinical efficacy, bioequivalence or superiority over other Picamilon products.
Source for the extracted data ↗ · Checked 2026-11-06
Patent claims and provenance
Formulation. The formulation identifies the sodium salt of N-nicotinoyl-GABA together with specified formulation components.
The composition patent is not evidence that every route or commercial formulation has the same clinical properties.
- Publication
- RU2149001C1 ↗ · 2000-05-20
- Earliest priority / filing
- 1999-09-09 / 1999-09-09
- Original applicant / assignee
- Открытое акционерное общество "Химикофармацевтический комбинат "Акрихин"
- Indexed status
- Not shown; official status unverified · checked 2026-11-06
- Patent family
- 20224731 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Nootropic drug and method of its preparing
Inventors: И.И. Тюляев; В.А. Быков; Б.И. Демченко; А.П. Зуев; Н.И. Юрченко.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- The composition patent is not evidence that every route or commercial formulation has the same clinical properties.
- A successful preparation example does not establish clinical efficacy, bioequivalence or superiority over other Picamilon products.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-20224731. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-06. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: И.И. Тюляев, В.А. Быков, Б.И. Демченко, А.П. Зуев, Н.И. Юрченко. Picamilon: pharmaceutical composition — RU2149001C1 RU2149001C1 · patent family 20224731 2000.
Molekul research summary: https://molekul.io/research/patent-ru2149001c1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry